Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment

Immune Checkpoint Inhibitors (ICIs) are improving the survival of cancer patients, however only the 20-30% of treated patients present clinical benefits. Toxicity represents the major cause of reduced dosage, delayed drug administration and therapy discontinuation. Hence in the context of multiple t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget
Hauptverfasser: Botticelli, Andrea, Zizzari, Ilaria, Mazzuca, Federica, Ascierto, Paolo Antonio, Putignani, Lorenza, Marchetti, Luca, Napoletano, Chiara, Nuti, Marianna, Marchetti, Paolo
Format: Artigo
Sprache:Inglês
Veröffentlicht: Impact Journals LLC 2016
Schlagworte:
Review
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352451/
https://ncbi.nlm.nih.gov/pubmed/27806346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12985
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge